1.97
+0.05(+2.60%)
Currency In USD
| Previous Close | 1.92 |
| Open | 1.87 |
| Day High | 1.97 |
| Day Low | 1.87 |
| 52-Week High | 3.26 |
| 52-Week Low | 1.33 |
| Volume | 10,940 |
| Average Volume | 44,518 |
| Market Cap | 20.04M |
| PE | -1.07 |
| EPS | -1.84 |
| Moving Average 50 Days | 2.14 |
| Moving Average 200 Days | 2.01 |
| Change | 0.05 |
If you invested $1000 in Cocrystal Pharma, Inc. (COCP) 10 years ago, it would be worth $11.17 as of February 05, 2025 at a share price of $1.97. Whereas If you bought $1000 worth of Cocrystal Pharma, Inc. (COCP) shares 5 years ago, it would be worth $293.15 as of February 05, 2025 at a share price of $1.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
GlobeNewswire Inc.
Dec 31, 2024 1:00 PM GMT
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged participants; virology results are uninterpre
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
GlobeNewswire Inc.
Oct 31, 2024 12:00 PM GMT
The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian influenza A PB2 protein, whereas current influenza vaccines offer no protection against pandemic avian influenza BOTHELL, Wash., Oct. 31